Articles tagged with Combination Therapies
A special issue of WORK Journal explores the importance of designing healthy workplaces that address musculoskeletal conditions, burnout, and chronic pain. The issue highlights the need for an interdisciplinary approach integrating medical, psychological, and occupational therapies to prevent work-related illness and injury.
Researchers at the University of Zurich have discovered a factor secreted by tumor cells that impeds the effectiveness of therapies. The POSTN gene plays an important role in resistant tumors and triggers resistance through its interaction with immune cells, particularly macrophages.
A novel combination of oncolytic virus and immune checkpoint inhibitor has shown remarkable efficacy in treating non-muscle invasive bladder cancer, with a complete response rate of 57.1% at 12 months. The therapy demonstrated durable responses, with a median duration of response not yet reached after a median follow-up of 26.5 months.
A new study demonstrates personalized phage therapy's effectiveness in treating antibiotic-resistant infections in animals, with a case of a cat healing from a persistent wound. The treatment combines a specific anti-Pseudomonas aeruginosa phage with ceftazidime, achieving full healing after 14 weeks.
Researchers at Baylor College of Medicine identified PKMYT1, a protein kinase associated with resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancers. The study found that combining a PKMYT1 inhibitor with chemotherapy drug gemcitabine selectively reduced the viability of resistant cancer cells.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
A retrospective cohort study found that PERT significantly reduced the incidence of acute pancreatitis episodes among children with recurrent or chronic pancreatitis. The study also identified genetic markers, such as SPINK1 mutation, that influence treatment outcomes and suggest a tailored approach to patient care.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Researchers at Johns Hopkins Medicine have developed a novel approach to target group 3 medulloblastoma tumors in mice, reducing tumor growth by 40-50% and extending survival by up to 84 days. The therapy uses antisense oligonucleotides to block lnc-HLX-2-7 from binding to the HLX promoter region.
A groundbreaking study found that combining partial normoxic recovery with senolytic Navitoclax significantly reduced sleepiness and improved cognitive function in mice with OSA. This suggests targeting accelerated senescence may be a promising avenue for improving treatment outcomes.
A Phase III trial demonstrates significantly improved progression-free survival and remission rates for patients with relapsed/refractory mantle cell lymphoma treated with the oral combination of ibrutinib and venetoclax. The treatment achieved an overall remission rate of 82% and a median PFS of 31.9 months.
Two studies led by UCLA researchers reveal how cancer cells use energy to survive and grow, shedding light on why some prostate cancers become resistant to hormone therapy. The findings highlight the importance of considering cell metabolism in developing new cancer treatments, particularly those targeting the androgen receptor.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
Researchers found that changing treatment can lead to significant improvement in mobility and quality of life for patients with advanced Parkinson's disease. A nationwide registry is planned to develop scientifically sound guidelines for combination therapies.
Researchers developed a ceria nanoparticle-immobilized mesenchymal stem cell nanovesicle hybrid system to treat rheumatoid arthritis. This approach provides both immediate pain relief through ROS scavenging and long-term immune tolerance by delivering immunomodulatory cytokines.
Dana-Farber Cancer Institute presents several studies on novel treatments, combination therapies, and personalized medicine for lung, kidney, and neuroendocrine tumors. The studies include pivotal trials on adagrasib with pembrolizumab for non-small cell lung cancer and belzutifan versus everolimus for clear cell renal cell carcinoma.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers found that patients' immune systems play a vital role in determining the duration of remission from multiple myeloma. Sustained minimal residual disease (MRD) negativity is associated with prolonged survival, with patients achieving MRD negativity for at least two years remaining free from multiple myeloma 10 years later.
A new gene-editing technique combines peptide nucleic acids and prokaryotic Argonautes to introduce targeted breaks in the genome. The approach, called PNP editing, offers advantages over CRISPR-based methods, including improved specificity and targeting.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
A new study led by Sandra Casimiro and Luís Costa found a promising molecular target, the RANK signaling pathway, that could be used in combination with standard care to avoid resistance to treatment in metastatic breast cancer. High levels of RANK in cancer cells are associated with resistance to treatment with CDK4/6 inhibitors.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
A large Danish study found that use of menopausal hormone therapy is associated with an increased rate of dementia and Alzheimer's disease. The study revealed a significant increase in dementia risk among women who received treatment at the age of 55 years or younger, even for short-term users.
A research team from HKUMed has developed a new platform to rapidly engineer and select the best precise genome editors for therapeutic applications. The platform allows for parallel testing of hundreds of base editor variants, enabling the selection of the most suitable ones with maximal efficiency and minimal undesired edits.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Scientists found that CXCL13-mediated recruitment of B cells helps predict response to immunotherapy treatment. This cooperation between T cells and B cells is associated with improved survival in patients treated with immunotherapy.
Cancer cells can hide and escape therapies leading to recurrence. Researchers identify three possible mechanisms: cancer stem cells, polyploidy, and senescence. Combination treatments involving chemoradiation-induced transitory senescence and senolytic therapies may be effective in preventing repopulation.
Researchers at University Hospital Bonn have developed a new approach to predict therapy response in patients with metastatic renal cell carcinoma by incorporating two simple blood parameters, CRP and albumin. This method improves the prediction of treatment response, especially in patients with disease control in the first follow-up.
A new study found that combining conventional speech therapy with singing can improve voice problems in individuals with Parkinson's disease. The tele-rehabilitation program showed significant improvements in voice intensity and Voice Handicap Index scores, suggesting a more effective treatment approach.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
Researchers successfully demonstrate AAV vector efficacy in aged animal models, showing robust hearing rescue in mice with a mutation equivalent to a defective human gene. The study suggests that virally mediated gene therapy could potentially treat genetic hearing loss, especially for patients diagnosed at advanced age.
Scientists at Temple University have developed a novel gene-editing strategy that disrupts the ability of HIV-1 virus to enter host cells by targeting a rare genetic disorder. This approach may offer another target for developing next-generation CRISPR technology for HIV elimination, while avoiding adverse effects on cell mortality.
Researchers investigated the roles of STAT3α and STAT3β in aggressive breast cancer and found that differential silencing of these isoforms leads to changes in STAT3 activation. This study emphasizes the importance of distinguishing between STAT3 isoforms for accurate cancer diagnosis and therapy.
A recent study found that immunotherapy alone resulted in a 89% favorable treatment response rate for patients with desmoplastic melanoma. This suggests that combination therapies may not be necessary for these patients, reducing the risk of toxicity.
Researchers at St. Jude Children's Research Hospital developed a novel combination therapy approach that uses both BET and GSK3 inhibitors against KMT2A mutated leukemia, overcoming drug resistance without increasing toxicity. The approach was confirmed in cell lines and xenograft mouse models, and holds promise for further development.
A phase 2 study found a 92% disease control rate with the combination of belzutifan and cabozantinib in pre-treated advanced kidney cancer patients. The treatment has a manageable safety profile, providing a potential alternative for patients experiencing disease progression on immunotherapy.
The magrolimab plus azacitidine regimen resulted in a complete response rate of 33% and partial response rate of 75%. Patients with TP53 mutations showed improved overall survival rates compared to previous studies.
A study found that the Omicron variant can dodge immune responses with just one or two dramatic mutations, while combinations of many mutations enable it to escape specific antibodies. The research suggests trade-offs between escaping immunity and maintaining infective capacity.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.
The work group reframed what is clinically meaningful to slow Alzheimer's disease progression, including the need for combination therapies and realistic expectations of benefits and risks. Slowing brain deterioration by four to six months in early stages may preserve function, leading to meaningful outcomes for patients and families.
The American College of Physicians recommends using cognitive behavioral therapy (CBT) or second-generation antidepressants as initial treatment for adults with moderate to severe major depressive disorder. The guideline also suggests considering combination therapy and discussing patient preferences when selecting a treatment.
Researchers found that regorafenib, a dual PDGFR α/β inhibitor, modifies the cancer microenvironment and enhances the efficacy of anti-PD-1 immunotherapy in advanced gastric cancers. This combination therapy boosts tumor infiltrating immune cells and reduces tumor fibroblasts.
Researchers found that combination therapy of buprenorphine and naloxone was as safe as buprenorphine alone during pregnancy, with similar outcomes in maternal health and newborn health. Larger studies are needed to confirm these findings.
Medical University of South Carolina researchers develop a novel LSD1 inhibitor that shows early promise at fighting neuroblastoma when paired with bortezomib. The combination boosts anti-tumor response and is a viable strategy for targeting high-risk MYCN-amplified neuroblastoma.
Rice University researchers are developing implants that can produce and deliver monoclonal anti-HIV antibody therapeutics for at least a year. The project aims to reduce the cost and improve the logistics of HIV treatment, making it more accessible and beneficial for patients worldwide.
Researchers at Karolinska Institutet found that internet-delivered anonymous cognitive behavioural therapy (CBT) significantly reduced the viewing of child sexual abuse material. The study, published in Internet Interventions, shows promise for a feasible and effective treatment approach.
A new meta-analysis commissioned by WHO informs updated treatment guidelines for uncomplicated malaria in the first trimester of pregnancy. The study finds that artemether-lumefantrine is as safe and possibly more effective than non-artemisinin-based treatments, including quinine, with significant reductions in adverse pregnancy outcomes.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
Researchers have designed a smart cell-based delivery system to treat Alzheimer's disease by targeting multiple pathologies, reducing the risk of side effects. The system uses bio-synthesizable drugs and immune cells to deliver combination therapy that addresses all pathologies in a targeted manner.
A phase 2 study found that combining nivolumab and ipilimumab showed a high response rate with durable results for patients with advanced Merkel cell carcinoma. The addition of stereotactic body radiation therapy did not improve efficacy in this dual checkpoint inhibitor therapy.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers have designed a phage combination therapy that precisely targets and suppresses gut bacteria associated with inflammatory bowel diseases (IBD). The team identified effective phages against IBD-contributing Kp strains, which attenuated inflammation and tissue damage in mice models.